Goldman Sachs Group Inc Paratek Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$1.37 - $2.54 $15,459 - $28,661	11,284 Added 44.27%	36,773 $93,000
Q1 2023 May 11, 2023	BUY	$1.37 - $2.54 $15,459 - $28,661	11,284 Added 44.27%	36,773 $93,000
Q4 2022 May 14, 2024	SELL	$1.67 - $2.51 $87,387 - $131,343	-52,328 Reduced 67.24%	25,489 $47,000
Q4 2022 Feb 13, 2023	SELL	$1.67 - $2.51 $87,387 - $131,343	-52,328 Reduced 67.24%	25,489 $47,000
Q3 2022 May 14, 2024	SELL	$1.96 - $2.93 $27,696 - $41,403	-14,131 Reduced 15.37%	77,817 $200,000
Q3 2022 Nov 10, 2022	SELL	$1.96 - $2.93 $27,696 - $41,403	-14,131 Reduced 15.37%	77,817 $0
Q2 2022 May 14, 2024	BUY	$1.73 - $3.09 $159,070 - $284,119	91,948 New	91,948 $177,000
Q2 2022 Aug 15, 2022	SELL	$1.73 - $3.09 $290,629 - $519,101	-167,994 Reduced 64.63%	91,948 $177,000
Q1 2022 May 16, 2022	BUY	$2.94 - $4.77 $16,549 - $26,850	5,629 Added 2.21%	259,942 $772,000
Q4 2021 Feb 14, 2022	SELL	$4.07 - $5.3 $73,772 - $96,067	-18,126 Reduced 6.65%	254,313 $1.14 Million
Q3 2021 Nov 10, 2021	BUY	$4.7 - $7.24 $1.28 Million - $1.97 Million	272,439 New	272,439 $1.32 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.